TY - JOUR
T1 - Redirecting the immune response
T2 - Role of adoptive T cell therapy
AU - Mondino, Anna
AU - Dardalhon, Valérie
AU - Michelini, Rodrigo Hess
AU - Loisel-Meyer, Severine
AU - Taylor, Naomi
PY - 2010/5/1
Y1 - 2010/5/1
N2 - Adoptive T cell therapy is aimed at overcoming constraints of the endogenous immune response. In patients with malignancies, this approach is based on the possibility of administering sufficient numbers of tumor-reactive lymphocytes under conditions in which they will promote a therapeutic response. Although this strategy is potentially applicable to a vast number of malignancies, its efficacy, to date, has been limited. This is likely related to several factors including an insufficient persistence and reactivation of infused cells, insufficient tumor infiltration, and the presence of an immunosuppressive environment. Here, we review the importance of pretransplantation host conditioning and posttransplantation strategies that have been shown to contribute to the therapeutic efficacy of infused T lymphocytes.
AB - Adoptive T cell therapy is aimed at overcoming constraints of the endogenous immune response. In patients with malignancies, this approach is based on the possibility of administering sufficient numbers of tumor-reactive lymphocytes under conditions in which they will promote a therapeutic response. Although this strategy is potentially applicable to a vast number of malignancies, its efficacy, to date, has been limited. This is likely related to several factors including an insufficient persistence and reactivation of infused cells, insufficient tumor infiltration, and the presence of an immunosuppressive environment. Here, we review the importance of pretransplantation host conditioning and posttransplantation strategies that have been shown to contribute to the therapeutic efficacy of infused T lymphocytes.
UR - http://www.scopus.com/inward/record.url?scp=77951967198&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77951967198&partnerID=8YFLogxK
U2 - 10.1089/hum.2010.033
DO - 10.1089/hum.2010.033
M3 - Article
C2 - 20201627
AN - SCOPUS:77951967198
VL - 21
SP - 533
EP - 541
JO - Human Gene Therapy
JF - Human Gene Therapy
SN - 1043-0342
IS - 5
ER -